Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Earns Buy Rating from SunTrust Banks, Inc.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating reiterated by equities research analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Tuesday. They presently have a $80.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $68.00. SunTrust Banks, Inc.’s target price suggests a potential upside of 34.43% from the stock’s current price.

Several other equities analysts also recently issued reports on the stock. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $68.67.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.54% during mid-day trading on Tuesday, hitting $59.51. 1,058,869 shares of the stock were exchanged. The company has a 50-day moving average of $55.14 and a 200 day moving average of $50.99. The stock’s market cap is $2.87 billion. Agios Pharmaceuticals has a one year low of $35.84 and a one year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $0.21. The firm had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $10.68 million. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The business’s quarterly revenue was up 62.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.47) EPS. On average, equities analysts predict that Agios Pharmaceuticals will post ($6.43) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Earns Buy Rating from SunTrust Banks, Inc.” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/08/08/agios-pharmaceuticals-inc-nasdaqagio-earns-buy-rating-from-suntrust-banks-inc.html.

In other news, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $50.02, for a total value of $150,060.00. Following the completion of the sale, the chief executive officer now owns 1,100 shares of the company’s stock, valued at $55,022. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total transaction of $95,895.60. Following the completion of the sale, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. Insiders have sold 79,120 shares of company stock valued at $4,557,207 in the last ninety days. 10.55% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in AGIO. State Board of Administration of Florida Retirement System raised its stake in Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the last quarter. Bank of Montreal Can raised its stake in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the last quarter. Creative Planning raised its stake in Agios Pharmaceuticals by 1.4% in the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 228 shares during the last quarter. Public Employees Retirement Association of Colorado raised its stake in Agios Pharmaceuticals by 5.2% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 323 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Agios Pharmaceuticals by 2.9% in the second quarter. BNP Paribas Arbitrage SA now owns 13,575 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 385 shares during the last quarter. 84.53% of the stock is owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply